F-star describes evolution of its asset-centric dealmaking

The Cambridge, UK-based bispecific antibody technology company F-star has so far created four asset-centric vehicles attracting up to EUR 200 million for its shareholders and the company. CEO John Haurum tells Informa Pharma Intelligence’s Mike Ward how its dealmaking strategy has evolved from F-star Alpha through to F-star Delta.